Eton Pharmaceuticals Financial Ratios
NASDAQ: ETONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Eton Pharmaceuticals ratio analysis
Eton Pharmaceuticals earned a net margin of -5.8% in FY 2025, up from -9.8% a year earlier. Gross margin was 53.5% compared with a median of 63.3% over the prior 6 years. Return on equity reached -17.6%, meaning Eton Pharmaceuticals generated -0.18 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.17 versus 1.22 the year before, and the current ratio was 1.57. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Eton Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Price / sales | 5.47 | 8.63 | 3.55 | 3.34 | 4.95 | 4,379.79 | 135.94 | — |
| Price / book | 16.73 | 13.78 | 7.26 | 5.42 | 6.13 | 9.69 | 12.36 | 1.40 |
| Gross margin | 53.5% | 60.0% | 66.6% | 67.4% | 87.1% | -1,017.9% | 52.8% | — |
| Operating margin | -1.1% | -6.7% | -3.8% | -38.9% | -6.8% | -69,515.4% | -1,939.6% | — |
| Net margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | -71,717.9% | -1,910.3% | — |
| Free cash flow margin | 12.7% | 2.4% | 21.5% | 22.5% | -21.7% | -57,425.6% | -1,994.0% | — |
| Return on equity (ROE) | -17.6% | -15.7% | -6.0% | -69.0% | -11.1% | -158.7% | -173.6% | -48.4% |
| Return on assets (ROA) | -5.0% | -5.0% | -2.9% | -36.0% | -7.1% | -106.3% | -107.3% | -45.0% |
| Debt / equity | 1.17 | 1.22 | 0.35 | 0.49 | 0.38 | 0.37 | 0.43 | — |
| Current ratio | 1.57 | 2.06 | 1.65 | 3.10 | 5.18 | 6.51 | 7.65 | 13.59 |
| Revenue growth | 104.9% | 23.3% | 48.9% | -2.7% | 55,879.5% | -95.9% | — | — |